Eric Lefkofsky is an American entrepreneur. He was born on September 2,1969 in Detroit, Michigan. Lefkofsky is the co-founder of Tempus, Groupon, Uptake Technologies, Mediaocean, Innerwokings, and Echo Global Logistics.Lefkofsky is also a Trustee of Lurie Children’s Hospital of Chicago, The Museum of Science and Industry and World Business of Chicago, and the Art Institute of Chicago.
He graduated from the University of Michigan and got his Juris Doctor at University of Michigan Law School. In 2006, Eric along with his wife founded the Lefkofsky Family Foundation. The Foundation is a private charitable foundation to help different communities. Lefkofsky now serves as a professor at the University of Chicago and wrote a book called Accelerated Disruption. His most famous business is the Tempus Labs. It has been rated as a top 10 Health Tech startup. It was founded in 2015. The company has teamed up with most of the National Cancer Institute Centers in the United States.
Tempus Labs does cancer testing that involves looking at tumors and taking DNA from the tumor cells. They also look at the immune system of the tumors and of the patients. They do drug testing to see what affects the tumors and what doesn’t, and use Medical Imaging. To put it simply, they enable Physicians to deliver personalized care for cancer patients depending on what types of tumors they have.
This is still a fairly new practice and they are still learning alot. By using a targeted approach to each cancer patient, they will be able to better treat the patient based on the individual type of cancer they have. Just like every person is different every persons cancer is different and is made up of unique cells. No two people should have the same cancer treatment. What works for one may not work for another. Tempus Labs are trying to get a better understanding of cancer cells and how they work, that way the doctors can offer better approaches to individual needs of the patients.
Learn More: www.crunchbase.com/person/eric-lefkofsky
At the core of all Clay Siegall’s professional achievement, Dr. Siegall has been committed and diligent about implementing the most significant research advancements. He is a professional who is purely guided by a real passion for helping patients and is incredibly motivated to stop their suffering. His enthusiasm in leading in new scientific achievements show no signs of slowing down.
Clay Siegall was the co-founder of Seattle Genetics in 1998. Clay Siegall formed Seattle Genetics on the grounds of rigorous research, discovery, passion for helping patients as well as drug development practices. Siegall is the current company’s Chief Executive Officer, Chairman, and the President. As a scientist, he places more emphasis on targeted cancer therapies. The current leadership position in achieving the 2011 FDA endorsement of its initial ADC product and developing antibody-drug conjugates (ADCs) has been accomplished under his guidance. ADCETRIS is now considered a brand that is recognized in more than 60 nations globally since collaborating with Takeda Pharmaceutical Company. The company is in the process of improving independent ADCs for the therapy of cancer.
The Company has enrolled into several vital permits for the technology of its ADC, incorporating with Abbvie, GlaxoSmithKline, Pfizer and Genentech (Roche) which have made 300 million plus to date. All this was achieved under the leadership of Clay Siegall. Through the company’s primary contribution in 2001, including private and public financings, Clay Siegal has led the company’s capital raising projects obtaining more than 1.2 million dollars.
Clay Siegall before joining Seattle Genetics worked in several institutes including National Institutes of health (1988-1991), National Cancer Institute and Bristol-Myers Squibb Pharmaceutical Research Institute (1991-1997). He works in Alder Biopharmaceuticals, Washington Roundtable, and Ultragenyx Pharmaceutical as a part of the company’s executives. Clay Siegall has received some awards including Young Entrepreneur of the Year and 2012 Pacific Northwest Ernst and the 2013 University of Maryland Alumnus of the Year for Math, Computer and Natural Sciences. In the University of Maryland, he attained a Bachelor of Science in Zoology and while at the George Washington University he got a Ph.D. in Genetics.